Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 69

Sort by

Sort Order Select

Journal Articles

Revumenib for patients with relapsed or refractory (R/R) Nucleophosmin 1–Mutated (NPM1m) Acute Myeloid Leukemia (AML): Outcomes by prior treatment in the phase 2 AUGMENT-101 study

Blood (2025) 146 (Supplement 1): 3418.

https://doi.org/10.1182/blood-2025-3418

Published: 2025

Journal Articles

Establishing the impact of effective donor-specific antibody (DSA) desensitisation in haploidentical and mismatched donor haematopoietic stem cell transplants: An Australian experience

Louis Do, Elizabeth O'Flaherty, Claire Dowsing, Peter Shuttleworth, Peter Bardy, Shafqat Inam, Ameya Hanamshet, Duncan Purtill, Abir Bhattacharyya, Gillian Huang, David Ritchie, John Moore, Ashish Bajel

Blood (2025) 146 (Supplement 1): 4199.

https://doi.org/10.1182/blood-2025-4199

Published: 2025

Journal Articles

Promising results from an ongoing Phase I multicenter study of senti-202, a first-in-class, CD33 and/or FLT3 & not endomucin (EMCN), selective off-the-shelf logic gated CAR NK cell therapy in adults with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Nosha Farhadfar, Stephen Strickland, Ashish Bajel, Alireza Eghtedar, Brian Garrison, Rochelle Emery, Kanya Rajangam, Gary Schiller, Farhad Ravandi

Blood (2025) 146 (Supplement 1): 1044.

https://doi.org/10.1182/blood-2025-1044

Published: 2025

Journal Articles

Immunological responses to blinatumomab treatment in B-acute lymphoblastic leukaemia (B-ALL) patients - australasian leukemia and lymphoma group ALL08 blam study

Joanne Davis, Mandy Ludford-Menting, Yilei (Evelyn) Yang, Darryl Johnson, John Kwan, John Moore, David Yeung, Nalini Pati, Michael Leahy, Matthew Greenwood, Ashish Bajel, Joanna Nkyekyer, Shaun Fleming, David Ritchie, Rachel Koldej, on behalf of Australasian Leukemia and Lymphoma Group (ALLG)

Blood (2025) 146 (Supplement 1): 3341.

https://doi.org/10.1182/blood-2025-3341

Published: 2025

Journal Articles

WU-CART-007, a CD7-directed allogeneic CAR-T cell therapy for R/R T-cell acute lymphoblastic leukemia/lymphoma: Phase 1/2 correlative data and long-term follow-up update

Alexander Hamil, Ibrahim Aldoss, Shannon Maude, Ashish Bajel, Armin Ghobadi, Rawan Faramand, Tom Leedom, Michael Rettig, Cherry Thomas, Ayman Kabakibi, Deepa Bhojwani

Blood (2025) 146 (Supplement 1): 4163.

https://doi.org/10.1182/blood-2025-4163

Published: 2025

Journal Articles

Identifying patients at risk of prolonged neutropenia and enhanced risk of complications during AZA-VEN induction for AML

Emily Batterham, Jules Higue, Ashish Bajel, Ing Tiong, Leopoldine Lapierre, Lydie Fourrier, Suzanne Tavitian, Sarah Bertoli, Christian Recher, Andrew Wei

Blood (2025) 146 (Supplement 1): 3465.

https://doi.org/10.1182/blood-2025-3465

Published: 2025

Journal Articles

Correlative data from an ongoing Phase 1, multicenter study of senti-202, a first-in-class, CD33 and/or FLT3 & not endomucin (EMCN), selective off-the-shelf CAR NK cell therapy for Acute Myeloid Leukemia (AML) is consistent with its clinical activity and unique logic gated mechanism of action

Muharrem Muftuoglu, Enping Hong, Nosha Farhadfar, Stephen Strickland, Ashish Bajel, Alireza Eghtedar, Gary Schiller, Mahesh Basyal, Li Li, Lawrence Naitmazi, Rochelle Emery, Timothy Lu, Brian Garrison, Kanya Rajangam, Farhad Ravandi, Michael Andreeff

Blood (2025) 146 (Supplement 1): 5921.

https://doi.org/10.1182/blood-2025-5921

Published: 2025

Journal Articles

Outcomes of patients with relapsed/refractory FLT3mut+ Acute Myeloid Leukemia who resumed gilteritinib therapy after HSCT: Post hoc analysis from the ADMIRAL and COMMODORE trials

Mark Levis, Alexander Perl, Jianda Hu, Heeje Kim, Vladimir Ivanov, Hisayuki Yokoyama, Naoko Hosono, Er-Lie Jiang, Dong-Yeop Shin, Bartlomiej Getta, Ashish Bajel, Jamie Jung-Hee An, Dina Elsouda, Juan Ariza, Jianxiang Wang

Blood (2025) 146 (Supplement 1): 42.

https://doi.org/10.1182/blood-2025-42

Published: 2025

Journal Articles

Time to complete remission is an independent determinant of survival after intensive chemotherapy in AML

Rithin Nedumannil, Michael Ashby, James Rowland, Jacques A. J. Malherbe, Jared Fairbank, Kelli Gray, Sun Loo, Matthew Wright, John Reynolds, Devendra Hiwase, Paula Marlton, Shaun Fleming, Ashish Bajel, Andrew H. Wei

Blood (2025) 146 (13): 1625–1629.

https://doi.org/10.1182/blood.2025028594

Published: 2025

Includes: Supplemental data

Journal Articles

Phase 1/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed/refractory T-cell malignancies

Blood (2025) 146 (10): 1163–1173.

https://doi.org/10.1182/blood.2025028387

Published: 2025

Includes: Supplemental data

Journal Articles

Menin inhibition with revumenib for NPM1 -mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study

Blood (2025) 146 (9): 1065–1077.

https://doi.org/10.1182/blood.2025028357

Published: 2025

Includes: Supplemental data

Journal Articles

Pretransplant MRD detection of fusion transcripts is strongly prognostic in KMT2A- rearranged acute myeloid leukemia

Blood (2024) 144 (24): 2554–2557.

https://doi.org/10.1182/blood.2024026605

Published: 2024

Includes: Supplemental data

Journal Articles

WUN101-01: First in Human Human (FIH) Phase 1 Study of WU-NK-101 (W-NK1) in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)

Blood (2024) 144 (Supplement 1): 4257.

https://doi.org/10.1182/blood-2024-201520

Published: 2024

Journal Articles

Evaluating a Multidisciplinary Model of Care for Inherited Bone Marrow Failure and Predisposition to Hematological Malignancy

Lucy C Fox, Nicole Den Elzen, Erin Goode, Kelsey Man, Lin Cheng, Stephanie Best, Jillian Francis, Laura Barth, Paul James, Karin A Thursky, Ashish Bajel, David S. Ritchie, Piers Blombery

Blood (2024) 144 (Supplement 1): 5015.

https://doi.org/10.1182/blood-2024-202704

Published: 2024

Journal Articles

Venetoclax-Based Measurable Residual Disease Directed Therapy in Acute Myeloid Leukemia Is Associated with Emergent TP53 Microclones in Remission

Ing Soo Tiong, Satwica Yerneni, Tamia Nguyen, Adam Ivey, Natasha S. Anstee, Emma Palfreyman, Ashish Bajel, Emad Uddin Abro, Devendra Hiwase, Andrew H Wei, Piers Blombery

Blood (2024) 144 (Supplement 1): 51.

https://doi.org/10.1182/blood-2024-201145

Published: 2024

Journal Articles

Azacitidine and Venetoclax Followed By Sequential Gilteritinib Is an Effective Alternative in Very Frail Patients with FLT3 -Mutated Acute Myeloid Leukemia

Rithin Nedumannil, Chelsea Matley, Ashish Bajel, Mark J. Levis, Andrew H Wei

Blood (2024) 144 (Supplement 1): 6060.

https://doi.org/10.1182/blood-2024-194547

Published: 2024

Journal Articles

Rural/Regional Place of Residence Impacts Post Allogeneic Bone Marrow Transplant Overall Survival of Australian Patients with Acute Myeloid Leukaemia: An Anztct Registry Study

Blood (2024) 144 (Supplement 1): 7923.

https://doi.org/10.1182/blood-2024-204669

Published: 2024

Journal Articles

Prior Azacitidine and Ongoing Transfusion Dependence in MDS Patients Are Associated with Inferior Survival after Allogeneic Stem Cell Transplant

Miles Horton, Becky Leung, Ricky Nelles, Matthew Rubic, Christopher McKinnely, Alia Cibich, Mark R Dowling, Stewart Hunt, Lynette C.Y. Chee, Ashleigh P Scott, David S. Ritchie, Devendra Hiwase, Duncan Purtill, Abir Bhattacharya, Glen A Kennedy, Ashish Bajel

Blood (2024) 144 (Supplement 1): 7440.

https://doi.org/10.1182/blood-2024-209705

Published: 2024

Journal Articles

Real-World Patterns of Care and Outcomes for Non-Favourable Risk Acute Myeloid Leukemia Treated with Intensive Chemotherapy across Australia and New Zealand- Data Linkage between the ALLG National Blood Cancer Registry (NBCR) and the Australia and New Zealand Transplant and Cellular Therapy (ANZTCT) Registry

Blood (2024) 144 (Supplement 1): 3799.

https://doi.org/10.1182/blood-2024-209389

Published: 2024

Journal Articles

WUC007-03: A Phase 2 Study of Anti-CD7 Allogenic CAR-T Cells (WT-7) in Patients with Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL)/Lymphoblastic Lymphoma (LBL)

Blood (2024) 144 (Supplement 1): 7225.

https://doi.org/10.1182/blood-2024-201825

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Revumenib for patients with relapsed or refractory (R/R) Nucleophosmin 1–Mutated (NPM1m) Acute Myeloid Leukemia (AML): Outcomes by prior treatment in the phase 2 AUGMENT-101 study

Establishing the impact of effective donor-specific antibody (DSA) desensitisation in haploidentical and mismatched donor haematopoietic stem cell transplants: An Australian experience

Promising results from an ongoing Phase I multicenter study of senti-202, a first-in-class, CD33 and/or FLT3 & not endomucin (EMCN), selective off-the-shelf logic gated CAR NK cell therapy in adults with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Immunological responses to blinatumomab treatment in B-acute lymphoblastic leukaemia (B-ALL) patients - australasian leukemia and lymphoma group ALL08 blam study

WU-CART-007, a CD7-directed allogeneic CAR-T cell therapy for R/R T-cell acute lymphoblastic leukemia/lymphoma: Phase 1/2 correlative data and long-term follow-up update

Identifying patients at risk of prolonged neutropenia and enhanced risk of complications during AZA-VEN induction for AML

Correlative data from an ongoing Phase 1, multicenter study of senti-202, a first-in-class, CD33 and/or FLT3 & not endomucin (EMCN), selective off-the-shelf CAR NK cell therapy for Acute Myeloid Leukemia (AML) is consistent with its clinical activity and unique logic gated mechanism of action

Outcomes of patients with relapsed/refractory FLT3mut+ Acute Myeloid Leukemia who resumed gilteritinib therapy after HSCT: Post hoc analysis from the ADMIRAL and COMMODORE trials

Time to complete remission is an independent determinant of survival after intensive chemotherapy in AML

Phase 1/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed/refractory T-cell malignancies

Menin inhibition with revumenib for NPM1 -mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study

Pretransplant MRD detection of fusion transcripts is strongly prognostic in KMT2A- rearranged acute myeloid leukemia

WUN101-01: First in Human Human (FIH) Phase 1 Study of WU-NK-101 (W-NK1) in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)

Evaluating a Multidisciplinary Model of Care for Inherited Bone Marrow Failure and Predisposition to Hematological Malignancy

Venetoclax-Based Measurable Residual Disease Directed Therapy in Acute Myeloid Leukemia Is Associated with Emergent TP53 Microclones in Remission

Azacitidine and Venetoclax Followed By Sequential Gilteritinib Is an Effective Alternative in Very Frail Patients with FLT3 -Mutated Acute Myeloid Leukemia

Rural/Regional Place of Residence Impacts Post Allogeneic Bone Marrow Transplant Overall Survival of Australian Patients with Acute Myeloid Leukaemia: An Anztct Registry Study

Prior Azacitidine and Ongoing Transfusion Dependence in MDS Patients Are Associated with Inferior Survival after Allogeneic Stem Cell Transplant

WUC007-03: A Phase 2 Study of Anti-CD7 Allogenic CAR-T Cells (WT-7) in Patients with Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL)/Lymphoblastic Lymphoma (LBL)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only